cyclophosphamide + durvalumab + epirubicin + nab-paclitaxel

This is a combination therapy regimen used primarily in the neoadjuvant treatment of triple-negative breast cancer (TNBC). The combination consists of four distinct agents: 1. **Cyclophosphamide**: An alkylating agent that works by interfering with DNA replication in rapidly dividing cells. 2. **Durvalumab (MEDI4736)**: A programmed cell death-ligand 1 (PD-L1) inhibitor that helps restore anti-tumor immune responses. 3. **Epirubicin**: An anthracycline antibiotic that inhibits DNA and RNA synthesis by intercalating between base pairs. 4. **Nab-paclitaxel (protein-bound paclitaxel)**: An antimicrotubule agent that promotes assembly and stabilization of microtubules, inhibiting normal dynamic reorganization of the microtubule network[6][8]. The regimen typically involves administration of nab-paclitaxel (often at 100-125 mg/m²) weekly for 12 weeks, with concurrent durvalumab (at doses of 3-10 mg/kg every 2 weeks), followed by dose-dense epirubicin and cyclophosphamide (EC) administered every 2 weeks for 4 cycles[1][2][7].